PAM
CCCC icon

Panagora Asset Management’s C4 Therapeutics CCCC Stock Holding History

Panagora Asset Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$228K Buy
+86,760
New +$204K ﹤0.01% 1057
2023
Q2 		– Sell
-107,891
Closed -$339K – 1291
2023
Q1 		$339K Buy
+107,891
New +$635K ﹤0.01% 1229

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Panagora Asset Management's CCCC Position: Q1 2026 in Review

Panagora Asset Management opened a new position in C4 Therapeutics (CCCC) in Q1 2026: 86,760 shares worth $228K. The stake represents ﹤0.01% of the portfolio and ranks #1057 among its holdings. This is a return to the name: Panagora Asset Management previously reported a position in CCCC as recently as Q1 2023.

Panagora Asset Management first reported a position in CCCC in Q1 2023 and has held it in 2 quarters since. The position peaked at $339K in Q1 2023. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Panagora Asset Management held 86,760 shares of C4 Therapeutics worth $228K as of Q1 2026.
  • C4 Therapeutics was a new Panagora Asset Management position in Q1 2026.
  • C4 Therapeutics made up ﹤0.01% of Panagora Asset Management's portfolio in Q1 2026, its #1057 holding.
  • Panagora Asset Management first reported a position in C4 Therapeutics in Q1 2023 and has held it in 2 quarters since.
  • Panagora Asset Management's C4 Therapeutics position peaked at $339K in Q1 2023.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Panagora Asset Management's 13F filing for Q1 2026, filed 14 May 2026.